# Fosanis

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/fosanis

- Industry: Software
- Headquarters: Berlin, Germany
- Website: www.mitmika.de
- Total disclosed funding: $11M
- Latest round: Series A (Mar 10, 2022)
- Investors on record: 6

## About

Fosanis GmbH, based in Berlin, Germany, operates in the online casino sector, offering innovative services designed to enhance user experience and engagement in gaming.Founded in 2017, Fosanis GmbH provides specialized services in the online casino market, particularly focusing on modern technology to improve user interfaces and gaming options. The company has executed three deals to date, with its most recent funding round being a Series A in March 2022, during which it raised EUR 10 million led by Debiopharm Innovation Fund, alongside other investors. The founders include Agnieszka ????, Armin Tligui, Gandolf Finke, and Jan Raue.Fosanis GmbH specializes in enhancing the online casino experience by offering innovative services aimed at both novice and veteran players. The company focuses on new online casinos with user-friendly interfaces and a variety of gaming options, including live dealer games and diverse slot offerings. Its clientele comprises casual gamers and serious bettors, particularly in the German market, emphasizing safety and compliance with local regulations.Fosanis GmbH generates revenue through partnerships with online casinos, primarily using a commission-based model that aligns with player engagement and transaction volume. The company earns a percentage from the revenue generated by casinos utilizing its platform. It provides comprehensive support to casino operators, enhancing user acquisition and the overall gaming experience without disclosing specific pricing plans.In March 2022, Fosanis GmbH raised EUR 10 million in Series A funding from lead investor Debiopharm Innovation Fund, with participation from other investors such as EquityPitcher, Ship2B Ventures, and MÜCKE ROTH & COMPANY. The company plans to utilize these funds to scale its oncology DTx platform, Mika, and expand its offerings internationally. Current initiatives include developing new products aimed at enhancing user engagement and exploring opportunities in new geographic regions.

## Funding rounds

- Series A, Mar 10, 2022, $11M — IBB Ventures, Ananda Impact Ventures, Debiopharm Innovation Fund, EquityPitcher Ventures, Ship2B Ventures, MÜCKE ROTH & COMPANY
- Seed, Mar 18, 2021 — IBB Ventures, Ananda Impact Ventures
- Angel, Aug 6, 2019 — IBB Ventures, Ananda Impact Ventures

## Investors

- IBB Ventures (https://capitalatlas.ai/funds/ibb-ventures) — Angel, Seed, Series A
- Ananda Impact Ventures (https://capitalatlas.ai/funds/ananda-impact-ventures) — Angel, Seed, Series A
- Debiopharm Innovation Fund (https://capitalatlas.ai/funds/debiopharm-innovation-fund) — Series A
- EquityPitcher Ventures (https://capitalatlas.ai/funds/equitypitcher-ventures) — Series A
- Ship2B Ventures (https://capitalatlas.ai/funds/ship2b-ventures) — Series A
- MÜCKE ROTH & COMPANY — Series A